Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Gynecol Oncol. 2023 Nov 17;179:115–122. doi: 10.1016/j.ygyno.2023.10.017

Figure 3:

Figure 3:

Efficacy of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer. Progression-free survival was assessed by an independent review committee.

PFS: progression-free survival; CI: confidence interval

Reprinted from Supplement to: The Lancet, Volume 22, Coleman RL, Lorusso D, Gennigens C, et al., Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study, Pages 609–619, Copyright (2021). Reprinted with permission from Elsevier.